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ABSTRACT
Title
 A RANDOMISED STUDY TO COMPARE RADICAL CONCURRENT 
CHEMORADIATION AGAINST RADICAL RADIOTHERAPY, AS TREATMENT 
OF CANCER OF THE CERVIX IN HIV INFECTED PATIENTS
Objectives
Cancer of the cervix is one of the commonest cancers in South African females. Up to 
30% of patients are HIV positive. The addition of chemotherapy to radiotherapy has been 
shown to significantly improve local control and survival and concurrent chemoradiation 
is the standard treatment for locally advanced cancer of the cervix. There is very limited 
literature available concerning the tolerance and efficacy of this treatment in HIV positive 
patients. This study aims to assess the acute toxicity of combined modality treatment in 
these patients. This study is part of a multicenter International Atomic Energy Agency 
sponsored study.
Materials and methods
Patients with FIGO stage IB2 to IIIB (without hydronephrosis) cervical cancer and who are 
HIV positive, were randomized to receive radiotherapy alone or chemo-radiation.  All 
patients received 46 Gy in 23 fractions external beam radiation and high-dose-rate-
i
brachytherapy 8 Gy x 3 fractions. Chemotherapy consisted of bolus Cisplatin 30mg/m2 
weekly given concurrently with the radiotherapy. Acute treatment toxicity was documented 
weekly during treatment.
Results
64 patients were recruited to the study. 31 patients were randomized to the chemoradiation 
arm and 33 patients to the radiation alone arm. Of the 64 patients recruited to the study, 6 in 
the chemoradiation arm and 5 in the radiation only arm did not receive any treatment and 
were therefore not evaluated. Stage IIB was the most common stage. The mean CD4 count 
was 410 in the chemoradiation arm vs. 358.4 in the radiation only arm at randomization. Only 
6 patients were on antiretroviral therapy at start of treatment, 3 in each arm. The number of 
chemotherapy cycles received by patients in the chemoradiation arm ranged between 0 and 5 
cycles. A total of 96 chemotherapy cycles were administered, with a median of 4 cycles per 
patient. Overall, at least 76% of patients received at least 4 cycles of chemotherapy. The full 
five intended courses of cisplatin were administered in 10 (40%) patients. Chemotherapy was 
not administered most commonly due to toxicity (renal, leucopaenia),  other reasons being 
logistical  and  non  compliance.  The  principle  major  adverse  effects  observed  were 
leucopaenia and cutaneous reactions. 
ii
The incidences of Grades 3 and 4 leucopaenia were significantly higher in the 
chemoradiation arm. 41 of the 51 evaluable patients at 3 months had complete responses to 
treatment, 20 (80%) in the chemoradiation arm and 21 (80.7%) in the radiation alone arm.
 
Conclusion
The  treatment  was  well  tolerated.  This  study  has  shown  that  radical  chemoradiation  in 
conventional doses can be given safely in HIV positive patients with invasive cervical cancer. 
Many patients did not receive the planned cisplatin dose due to various factors not related to 
toxicity. Chemoradiotherapy is a resource intensive treatment, involving considerable input 
from doctors, nurses, radiographers and pharmacists  and a high degree of coordination is 
necessary for treatment to be delivered effectively. In general the same principles that guide 
the oncologic management of immunocompetent patients should be applied to HIV patients. 
Further follow up is required to assess survival functions. Larger studies assessing toxicity 
and  efficacy  of  concurrent  chemoradiation  in  cervical  cancer  patients  who are  also  HIV 
positive need to be done.
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